Citations

Mayo Clinic

Showing 10 of 108522 citations.

The unstable knee
Haas, Steven B., Abdel, Matthew P.

The Bone & Joint Journal | November 7, 2014 | Volume: 96-B | Issue: 11_Supple_A | Pages: 112-114

10.1302/0301-620x.96b11.34325 | PMID 25381421 Get It

Instability after total knee replacement (TKR) accounts for 10% to 22% of revision procedures. All patients who present for evaluation of instability require a thorough history to be taken and physical examination, as well as appropriate imaging. Deep periprosthetic infection must be ruled out by laboratory testing and an aspiration of the knee must be carried out. The three main categories of instability include flexion instability, extension instability (symmetric and asymmetric), and genu recurvatum. Most recently, the aetiologies contributing to, and surgical manoeuvres required to correct, flexion instability have been elucidated. While implant design and patient-related factors may certainly contribute to the aetiology, surgical technique is also a significant factor in all forms of post-operative instability.Cite this article: Bone Joint J 2014;96-B(11 Suppl A):112–4.
Langerhans cell activation in diabetic small fiber polyneuropathy
Piccione, Ezequiel, Engelstad, JaNean K., Wieland, Carilyn N. , Klein, Christopher J. , Piccione, Ezequiel Agustin, Wieland, Carilyn, Engelstad, JaNean , Klein, Christopher J

Neurology Neuroimmunology & Neuroinflammation | November 7, 2014 | Volume: 1 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000042 | PMID 25386567 Get It

Transseptal puncture to facilitate device closure of “long‐tunnel” patent foramen ovale
Thompson, Alex , Hagler, Donald J. , Taggart, Nathaniel W. , Thompson, Alex J, Taggart, Nathaniel W

Catheterization and Cardiovascular Interventions | November 7, 2014 | Volume: 85 | Issue: 6 | Pages: 1053-1057

10.1002/ccd.25723 | PMID 25380406 Get It

BackgroundPatent foramen ovale (PFO) is common and may predispose to paradoxical embolism. Transcatheter device closure of PFO can be challenging in certain cases of “long‐tunnel” PFO morphology. We report our experience with device closure of long‐tunnel PFO using transseptal puncture.MethodsWe retrospectively reviewed all cases of PFO device closure using transseptal puncture at the Mayo Clinic from January 1, 2010 to September 30, 2013. We arbitrarily defined a PFO tunnel configuration as a tunnel length ≥ 12 mm as observed in intracardiac echocardiography (ICE) at the time of device closure.ResultsTwelve patients (mean age 40.8 [range 15–67] years; 7 males [58%]) underwent PFO device closure with transseptal puncture. The most common indication for PFO closure was previous stroke (n = 7, 58%). Median tunnel length measured by ICE was 15 mm (12–20 mm). GORE® HELEX® Septal Occluder was used for closure in all but one patient. The only significant procedural complication was a minor perforation of the left atrial wall during attempted septal puncture, which resulted in a trivial pericardial effusion that resolved without intervention. At latest follow‐up (mean 543 days, [range 170–1162]) one patient had a residual shunt and subsequently died due to complications during surgical PFO closure. No recurrent strokes or TIAs were reported.ConclusionThough not without risk, transseptal puncture can be a valuable tool for facilitating device closure of long‐tunnel type PFOs. GORE® HELEX® Septal Occluder may be an effective option for facilitating device closure for patients with long‐tunnel type PFO. © 2014 Wiley Periodicals, Inc.
Editorial: sprue‐like enteropathy associated with olmesartan – broadening the differential diagnosis of enteropathy
Rubio‐Tapia, Alberto

Alimentary Pharmacology & Therapeutics | November 7, 2014 | Volume: 40 | Issue: 11-12 | Pages: 1362-1363

10.1111/apt.13000 | PMID 25376200 Get It

Pathogenic Ischemic Stroke Phenotypes in the NINDS-Stroke Genetics Network
Ay, Hakan , Arsava, Ethem Murat , Andsberg, Gunnar , Benner, Thomas, Brown, Robert D. , Chapman, Sherita , Delavaran, Hossein , Dichgans, Martin , Engström, Gunnar , Giralt‐Steinhauer, Eva , Grewal, Raji P., Gwinn, Katrina , Jiménez-Conde, Jordi , Katsnelson, Michael , Kissela, Brett , Kittner, Steven J. , Kleindorfer, Dawn , Labovitz, Daniel , Lanfranconi, Silvia , Lee, Jin‐Moo , Lehm, Manuel, Lemmens, Robin , Levi, Christopher , Li, Linxin , Lindgren, Arne, Markus, Hugh S. , McArdle, Patrick F. , Melander, Olle , Peddareddygari, Leema Reddy , Pedersén, Annie , Pera, Joanna , Rannikmäe, Kristiina , Rexrode, Kathryn M. , Rich, Stephen S. , Rothwell, Peter M. , Schmidt, Reinhold , Schürks, Markus , Seiler, Stephan , Słowik, Agnieszka , Sudlow, Cathie , Thijs, Vincent , Woodfield, Rebecca, Worrall, Bradford B. , Chapman, Sherita N, Cole, John W. , Giralt-Steinhauer, Eva, Jern, Christina, Jood, Katarina, Kleindorfer, Dawn O, Labovitz, Daniel L, Levi, Chris, Rhodes, David, Rundek, Tatjana , Slowik, Agnieszka, Jern, Christina , Jood, Katarina , Lindgren, Arne, Norrving, Bo , Rhodes, David , Roquer, Jaume , Rosand, Jonathan M. , Sacco, Ralph L. , Sharma, Pankaj Kumar , Meschia, James F. , Dichgans, Martin , Rich, Stephen S , Lemmens, Robin , Lee, Jin-Moo

Stroke | November 7, 2014 | Volume: 45 | Issue: 12 | Pages: 3589-3596

10.1161/strokeaha.114.007362 | PMID 25378430 Get It

Background and Purpose— NINDS (National Institute of Neurological Disorders and Stroke)-SiGN (Stroke Genetics Network) is an international consortium of ischemic stroke studies that aims to generate high-quality phenotype data to identify the genetic basis of pathogenic stroke subtypes. This analysis characterizes the etiopathogenetic basis of ischemic stroke and reliability of stroke classification in the consortium. Methods— Fifty-two trained and certified adjudicators determined both phenotypic (abnormal test findings categorized in major pathogenic groups without weighting toward the most likely cause) and causative ischemic stroke subtypes in 16 954 subjects with imaging-confirmed ischemic stroke from 12 US studies and 11 studies from 8 European countries using the web-based Causative Classification of Stroke System. Classification reliability was assessed with blinded readjudication of 1509 randomly selected cases. Results— The distribution of pathogenic categories varied by study, age, sex, and race ( P <0.001 for each). Overall, only 40% to 54% of cases with a given major ischemic stroke pathogenesis (phenotypic subtype) were classified into the same final causative category with high confidence. There was good agreement for both causative (κ 0.72; 95% confidence interval, 0.69–0.75) and phenotypic classifications (κ 0.73; 95% confidence interval, 0.70–0.75). Conclusions— This study demonstrates that pathogenic subtypes can be determined with good reliability in studies that include investigators with different expertise and background, institutions with different stroke evaluation protocols and geographic location, and patient populations with different epidemiological characteristics. The discordance between phenotypic and causative stroke subtypes highlights the fact that the presence of an abnormality in a patient with stroke does not necessarily mean that it is the cause of stroke.
The Rare Cancer Network: Ongoing Studies and Future Strategy
Özşahin, Mahmut , Mirimanoff, René-Olivier, Thariat, Juliette , Sun, Xu , Atalar, Banu , Lassen–Ramshad, Yasmin , Uğurluer, Gamze , Hallemeier, Christopher L. , Houtte, Paul Van , Krengli, Marco , Zhang, Lan Jun, Funk, Ryan K., Rooney, Jessica, Miller, Robert C. , Hallemeier, Christopher, Chang, Kenneth , Funk, Ryan, Mirimanoff, R.O., Krishnan, Sunil , Hallemeier, Christopher Leigh , Chang, Kenneth Tou En , Thariat, Juliette

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 91-94

10.4081/rt.2014.5465 | PMID 25276326 Get It

The Rare Cancer Network (RCN) was formed in the early 1990's to create a global network that could pool knowledge and resources in the studies of rare malignancies whose infrequency prevented both their study with prospective clinical trials. To date, the RCN has initiated 74 studies resulting in 46 peer reviewed publications. The First International Symposium of the Rare Cancer Network took place in Nice in March of 2014. Status updates and proposals for new studies were heard for fifteen topics. Ongoing studies continue for cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas. New proposals were presented at the symposium for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, tumors of the ampulla of Vater, salivary gland tumors, anorectal melanoma, midline nuclear protein in testes carcinoma, pulmonary lymphoepithelioma-like carcinoma, adenoid cystic carcinoma of the trachea, osteosarcomas of the mandible, and extra-cranial hemangiopericytoma. This manuscript presents the abstracts of those proposals and updates on ongoing studies, as well a brief summary of the vision and future of the RCN.
History of the Rare Cancer Network and past Research
Mirimanoff, René-Olivier, Özşahin, Mahmut , Thariat, Juliette , Özyar, Enis , Schick, Ulrike , Pehlivan, Berrin , Krengli, Marco , Franzetti-Pellanda, Alessandra , Vees, Hansjörg, Scandolaro, Luciano , Belkacémi, Yazid , Villà, S. , İğdem, Şefik , Lutsyk, Myroslav, Miller, Robert C. , Mirimanoff, R.O., Cai, Ling , Thariat, Juliette

Rare Tumors | November 7, 2014 | Volume: 6 | Issue: 3 | Pages: 86-90

10.4081/rt.2014.5462 | PMID 25276325 Get It

Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents. The network held its first international symposium in Nice, France, on March 21-22, 2014. The proceedings of that meeting are presented in two companion papers. This manuscript reviews the history of the growth of the RCN and contains the abstracts of fourteen oral presentations made at the meeting of prior RCN studies. From 1993 to 2014, 74 RCN studies have been initiated, of which 54 were completed, 10 are in progress or under analysis, and 9 were stopped due to poor accrual. Forty-four peer reviewed publications have been written on behalf of the RCN.
ERG expression in chondrogenic bone and soft tissue tumours
Shon, Wonwoo , Folpe, Andrew L. , Fritchie, Karen , Fritchie, Karen J.

Journal of Clinical Pathology | November 7, 2014 | Volume: 68 | Issue: 2 | Pages: 125-129

10.1136/jclinpath-2014-202601 | PMID 25378537 Get It

Aim We studied ERG expression in a large series of chondrogenic bone and soft tissue tumours to assess the value of ERG as a possible marker of chondroid/cartilaginous differentiation. Methods Formalin-fixed, paraffin-embedded whole sections from 111 bone and soft tissue tumours with chondroid differentiation or a morphology that may mimic cartilaginous differentiation were retrieved. Immunohistochemistry was performed using anti-ERG monoclonal antibody directed against the N terminus. Nuclear staining was scored as negative (<5%), 1+ (5%–25%), 2+ (26%–50%), 3+ (>51%). Results Nuclear ERG expression was seen in all cases of soft tissue chondroma (8), chondromyxoid fibroma (7), chondroblastic osteosarcoma (6) and clear cell chondrosarcoma (1). 10/12 conventional chondrosarcomas were also positive for ERG. In cases of dedifferentiated chondrosarcoma, the well-differentiated component was positive in 7/9 cases, while all dedifferentiated foci were negative. In cases of mesenchymal chondrosarcoma, the hyaline cartilage component was positive in 2/4 cases, whereas the primitive component in all cases was negative. Variable positivity was identified in extraskeletal myxoid chondrosarcomas (4/9), chondroblastomas (3/8) and mixed tumours/myoepitheliomas (2/11). Only 1/12 chordoma was positive for ERG (1+). Interestingly, 15/17 enchondromas were negative for ERG. Conclusions In this study, we further characterise the expression of ERG in mesenchymal tumours and found relatively constant nuclear ERG expression in selected chondrogenic tumours including conventional chondrosarcoma, chondromyxoid fibroma, chondroblastic osteosarcoma and clear cell chondrosarcoma. We also show that ERG may be a helpful ancillary tool in certain select diagnostic scenarios and that awareness of ERG expression in tumours with cartilaginous differentiation is important.
Prevalence and risk factors for dysphagia: a USA community study
Cho, Seyoung , Choung, Rok Seon , Saito, Y. A., Schleck, C. D., Zinsmeister, A. R., Locke, G. Richard, Talley, N. J., Saito, Y. A., Choung, Rok Seon

Neurogastroenterology & Motility | November 7, 2014 | Volume: 27 | Issue: 2 | Pages: 212-219

10.1111/nmo.12467 | PMID 25376877 Get It

AbstractBackgroundDysphagia is considered an alarm symptom but detailed population‐based data on dysphagia are lacking. We aimed to estimate in a representative USA Caucasian population, the prevalence of dysphagia and potential risk factors.MethodsA modified version of the previously validated Bowel Disease Questionnaire was mailed to a population‐based cohort (n = 7640) of Olmsted County, MN. Dysphagia was measured by one validated question ‘In the last year, how often have you had difficulty swallowing (a feeling that food sticks in your throat or chest)?’ The medical records were reviewed for organic causes of dysphagia. The associations of reported frequency of dysphagia with potential risk factors were assessed using logistic regression models.Key ResultsThe sex‐specific, age‐adjusted (US White 2000) prevalence for dysphagia experienced at least weekly was 3.0% (95% CI: 2.2, 3.7) in females and 3.0% (95% CI: 2.0, 4.0) in males. Those with frequent heartburn (OR = 5.9 [4.0, 8.6]) and acid regurgitation (OR = 10.6 [6.8, 16.6]) were significantly more likely to report frequent dysphagia. Proton pump inhibitor (PPI) use was significantly associated with frequent (3.1, 95% CI 2.2, 4.4) and infrequent dysphagia (1.5, 955 CI 1.3, 1.8). Gastro‐esophageal reflux disease (GERD) was the most common diagnosis in those reporting dysphagia on the medical record; other organic explanations were rare and only found in the frequent dysphagia group.Conclusions & InferencesFrequent dysphagia is not rare in the community (3%), occurs in both women and men across all adult age groups, and is most likely to indicate underlying GERD.